Piper Sandler Reiterates Neutral Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “neutral” rating reiterated by equities researchers at Piper Sandler in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $43.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $45.00. Piper Sandler’s price objective points to a potential upside of 48.81% from the company’s current price.

Other research analysts have also issued research reports about the company. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Needham & Company LLC reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ COLL traded down $0.21 during midday trading on Friday, reaching $28.90. 442,488 shares of the company were exchanged, compared to its average volume of 479,968. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a 1 year low of $28.01 and a 1 year high of $50.79. The stock has a fifty day simple moving average of $34.86 and a 200 day simple moving average of $37.13. The stock has a market cap of $937.10 million, a P/E ratio of 14.17 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.68 EPS. On average, research analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Collegium Pharmaceutical in the second quarter worth $196,972,000. Deutsche Bank AG purchased a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth $1,270,000. Bank of New York Mellon Corp purchased a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth $8,506,000. State of Wyoming acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth $218,000. Finally, One Wealth Advisors LLC acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth $310,000.

Key Headlines Impacting Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium reported second-quarter adjusted EPS of $1.92, above the roughly $1.68-$1.72 analyst estimates and up from $1.68 a year earlier. Revenue reached $199.9 million, up 6% year over year and broadly in line with estimates. Collegium Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The ADHD portfolio continued to grow: JORNAY PM revenue increased 41% to $46.1 million, while the newly acquired AZSTARYS contributed $12.9 million during its partial quarter. Collegium also raised its 2026 AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million. 2026 Q2 Results Earnings Presentation
• Positive Sentiment: Operating cash flow was a solid $71.3 million, and adjusted EBITDA rose 8% year over year to $113.8 million, supporting the company’s ability to integrate AZSTARYS and invest in growth.
• Neutral Sentiment: Needham lowered its price target to $46 from $56 but maintained a Buy rating, implying substantial long-term upside despite reduced near-term expectations. Needham Price Target Update
• Negative Sentiment: Collegium cut 2026 product revenue guidance to $825 million-$855 million from $865 million-$895 million, below the approximately $872.4 million consensus estimate. Adjusted EBITDA guidance also fell to $445 million-$470 million from $475 million-$500 million, primarily because of lower pricing and sales for authorized generic Nucynta products.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta franchise revenue fell 24% and Xtampza ER revenue fell 14%. GAAP results also showed a $15.1 million net loss, while operating expenses increased 45%, partly reflecting acquisition-related costs. Collegium Q2 Earnings and Guidance
• Negative Sentiment: An analyst downgrade contributed to the shares reaching a new 12-month low, reinforcing concerns about slowing pain-product sales and the lowered outlook. Collegium Hits New 12-Month Low on Analyst Downgrade

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.